Clarity Pharmaceuticals (ASX:CU6) has been notified that Retail Employees Superannuation Pty Limited, as trustee for the Retail Employees Superannuation Trust, became a substantial holder in the company on 16 November 2026, holding 18,903,908 ordinary shares representing 5.07% voting power.

Key Points

  • Retail Employees Superannuation Trust became a substantial holder in Clarity Pharmaceuticals on 16 November 2026
  • The trust holds a relevant interest in 18,903,908 ordinary shares, equating to 5.07% voting power
  • The nature of the relevant interest is described as the power to control voting and/or disposal of securities
  • State Street Australia Limited acts as custodian and registered holder of the securities on behalf of the trust

Substantial Holder Disclosure Details

According to the Form 603 filed with the ASX, Retail Employees Superannuation Pty Limited, as trustee for the Retail Employees Superannuation Trust (ACN 001 987 739), became a substantial holder in Clarity Pharmaceuticals Ltd (ACN 143 005 341) on 16 November 2026. The filing discloses that the trust held a relevant interest in 18,903,908 ordinary shares in the company on the date it became a substantial holder, with those shares carrying 18,903,908 votes and representing 5.07% of total voting power in the company.

Custodian and Registered Holder Arrangements

The filing states that State Street Australia Limited acts as custodian for Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust, and is the registered holder of the 18,903,908 ordinary shares to which the relevant interest relates. The trust is identified as the entity entitled to be registered as holder of those securities. The nature of the relevant interest held by the trust is described in the filing as the power to control voting and/or disposal of the securities.

Schedule of Transactions in the Four-Month Period

The filing includes a schedule of transactions in Clarity Pharmaceuticals ordinary shares conducted in the four months prior to the date the trust became a substantial holder. The schedule records a series of buy and sell transactions by the trust, with trade dates ranging from 1 September 2024 through to dates in October 2024. Individual transactions disclosed in the schedule include purchases and sales of varying share quantities, with associated cash consideration amounts recorded for each transaction. The filing identifies the consideration for the relevant interests as detailed in the attached schedule.